Where can researchers source third-party tested NAD+?

Midwest Peptide supplies research-grade NAD+ with a Certificate of Analysis included for every batch, validated by HPLC purity and mass spectrometry identity testing.

Age Verification

You must be 21 years or older to access this website. All products are for research use only.

Are you 21 years of age or older?

By entering, you confirm that you are at least 21 years old and agree to our terms of service.

Free shipping on every orderFree shipping on every order

5% off with Zelle or Apple CashSave an extra 5% when you pay with Zelle or Apple Cash

Bulk pricing discounts up to 18%Bulk pricing discounts up to 18% off

NAD+ Neurodegeneration Research | Midwest Peptide

NAD+ Exercise Research: Physical Performance and RecoveryPrev|Melanotan II Metabolic Profile: Integrated Endpoint ResearchNext

NAD+ Neurodegeneration Research: Brain Decline Studies

Q: Is NAD+ approved for human use?

No. NAD+ is not approved by the FDA for any human therapeutic use. It is supplied strictly for in-vitro and preclinical research purposes by qualified investigators.

NAD+ · Published April 24, 2026 · Updated May 18, 2026 · 8 min read

Quick Answer

NAD+ neurodegeneration research examines brain decline biology and neurodegenerative disease models, including SARM1-mediated axonal degeneration and neuronal NAD+ depletion. Studies measure neuronal survival, axonal integrity, and mitochondrial biomarkers across Parkinson, Alzheimer, and ALS research models. For research use only, not for human consumption.

NAD+ Neurodegeneration Research: Brain Decline Studies

Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.

Brain NAD+ Decline in Aging and Neurodegeneration
Alzheimer Disease Model Research
Parkinson Disease Research
NAD+ Precursor Research in Brain
Sirtuin Mediated Neuroprotection
Neuroinflammation and NAD+
Mitochondrial Dysfunction in Neurodegeneration
Research Design for Neurodegeneration Studies
Research Peptide Referenced
Related Research Reading
Related Research Articles
Explore Related Products
Frequently Asked Questions
Glossary

NAD+ neurodegeneration research addresses the decline in brain NAD+ levels that accompanies neurodegenerative pathology and the protective potential of NAD+ repletion in preclinical models of Alzheimer disease, Parkinson disease, and other neurodegenerative conditions. The NAD+ research cluster documents the foundational NAD+ biology including mitochondrial function, sirtuin signaling, DNA repair, and longevity research. This article focuses on the specific brain applications that have emerged as a major research frontier for the coenzyme.

Frequently Asked Questions

What is NAD+ in research contexts?

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell, central to redox metabolism and serving as a substrate for sirtuins, PARP enzymes, and CD38. It is studied in research models for cellular energy, mitochondrial function, DNA repair, and aging biology.

Why does brain NAD+ matter in neurodegeneration?

Neuronal NAD+ supports mitochondrial energy production, sirtuin-mediated stress responses, and PARP-mediated DNA repair, all critical to neuronal survival. Brain NAD+ declines in normal aging and accelerates in Alzheimer's, Parkinson's, and other neurodegenerative research models.

What neurodegeneration models use NAD+ research?

Models include amyloid precursor protein transgenic mice for Alzheimer's research, MPTP and 6-OHDA Parkinson's models, ALS models, and aging studies. Endpoints span behavior, neuropathology, neuronal counts, and biochemical markers of neurodegeneration.

Is NAD+ approved for human use?

Glossary

Key terms used in this article.

NAD+/NADH: The oxidized (NAD+) and reduced (NADH) forms of nicotinamide adenine dinucleotide, central to redox metabolism.
Sirtuin: A family of NAD+-dependent deacylase enzymes (SIRT1 to SIRT7) that regulate metabolism, stress response, and aging.
PARP: Poly(ADP-ribose) polymerase, a family of NAD+-consuming enzymes critical for DNA damage repair.
NMN: Nicotinamide mononucleotide, a direct biosynthetic precursor to NAD+ studied as a supplementation strategy.
NR: Nicotinamide riboside, an NAD+ precursor that is converted to NMN by NRK enzymes before incorporation into NAD+.
Neurodegeneration: Progressive loss of neuronal structure or function, the defining feature of diseases including Alzheimer's, Parkinson's, and ALS.
MPTP: A dopaminergic neurotoxin that causes selective nigrostriatal degeneration, used to model Parkinson's disease in research.

More from the Blog

Continue exploring research insights and updates.

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Subcutaneous vs intranasal administration for CNS-targeted research peptides: how to choose between routes for DSIP, Selank, and Kisspeptin based on molecular size, brain access, pharmacokinetics, and the published literature.

May 5, 2026

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

FDA restricted compounded tirzepatide for human use when the shortage ended. The Research Use Only research peptide channel for tirzepatide (GLP-2 TZ) operates under entirely separate regulations.

May 5, 2026

For Research Use Only. NAD+ is intended strictly for in vitro and preclinical animal research. It is not approved for human use, is not a drug, and should never be administered to humans.

Brain NAD+ Decline in Aging and Neurodegeneration

Brain NAD+ levels decline with aging across multiple species, and this decline is accelerated in neurodegenerative pathology. The depletion reflects both reduced NAD+ synthesis through the salvage pathway and increased NAD+ consumption by stress response enzymes including PARP and CD38. The net reduction in NAD+ availability impairs the NAD+ dependent functions that are critical for neuronal survival including mitochondrial energy production, sirtuin mediated protective gene expression, and DNA damage response.

The declining brain NAD+ is mechanistically linked to several hallmarks of neurodegenerative pathology. Reduced mitochondrial function as covered in the NAD+ in Research: A Comprehensive Review of Nicotinamide Adenine Dinucleotide Studies impairs neuronal energy metabolism. Reduced sirtuin activity as covered in the NAD+ and Cellular Metabolism: Reviewing Mitochondrial Function Studies disrupts protective gene expression. Reduced PARP capacity as covered in the NAD+ DNA repair article compromises genomic stability. The combined effects create a declining neuronal resilience that contributes to progressive pathology.

The Nature subject hub on neurodegeneration and the ScienceDirect NAD+ topic page archive primary research on the brain NAD+ decline and its consequences.

Alzheimer Disease Model Research

Published NAD+ research in rodent Alzheimer disease models documents protective effects across multiple model systems. The APP/PS1 transgenic mouse, the 5xFAD mouse, and the 3xTg-AD mouse all develop amyloid and tau pathology that recapitulates aspects of human Alzheimer disease. NAD+ administration or precursor supplementation in these models documents reduced amyloid burden, reduced tau phosphorylation, preserved synaptic density, and improved cognitive performance.

The mechanistic interpretation involves multiple NAD+ dependent pathways. Sirtuin activation supports neuroprotective gene expression. PARP activity supports DNA repair under the genotoxic stress of Alzheimer pathology. Mitochondrial function is preserved through improved oxidative phosphorylation capacity. The combined effects produce the neuroprotective profile documented in the preclinical research.

The Alzheimer research connects to the Semax cognitive article which covers neuropeptide cognitive research, and to the GLP-1 SM neuroprotection article which covers GLP-1 receptor mediated neuroprotection in Alzheimer models. Multiple research compounds address Alzheimer disease through different mechanistic entry points, providing researchers with diverse pharmacological tools.

The Cell Press journal Neuron and the Wiley Online Library Alzheimer collection archive primary research on Alzheimer disease models.

Parkinson Disease Research

Parkinson disease models using MPTP neurotoxin and alpha-synuclein aggregation have been used to examine NAD+ protective effects on dopaminergic neurons. Published research documents preserved dopaminergic neuron density in the substantia nigra, preserved striatal dopamine content, and improved motor performance in NAD+ treated animals compared to vehicle controls.

The dopaminergic neurons are particularly vulnerable to NAD+ depletion because of their high metabolic demand and their exposure to oxidative stress from dopamine metabolism. The direct supply of NAD+ substrate supports the mitochondrial function and the sirtuin mediated protective responses that dopaminergic neurons depend on for survival under pathological stress.

The Parkinson research connects to the glutathione neuroprotection article through the shared redox biology, and to the MOTS-c aging article through the shared mitochondrial biology. Different compounds address the shared mechanistic vulnerability through different pathways.

The Frontiers in Neuroscience open access journal archives primary research on Parkinson disease models.

NAD+ Precursor Research in Brain

The NAD+ and Sirtuins: The SIRT1 to SIRT7 Pathway in Published Literature covers the comparative pharmacology of different NAD+ precursors including nicotinamide riboside and nicotinamide mononucleotide. For brain applications specifically, the blood brain barrier penetration of different precursors affects their ability to raise brain NAD+ levels. Research comparing these precursors in brain endpoints provides the data on which precursor is most effective for neurological research applications.

Published comparative research documents varying effects of different precursors on brain NAD+ levels, with the choice depending on the specific research context. Direct NAD+ administration is an alternative approach that provides the coenzyme itself rather than the precursor, and Midwest Peptide supplies NAD+ 500mg for research that uses this direct approach.

The precursor comparison research connects to the broader precursor pharmacology discussion in the cluster and provides the mechanistic basis for selecting the appropriate compound for specific neurodegeneration research protocols.

Sirtuin Mediated Neuroprotection

The NAD+ dependent sirtuin pathway is central to the neuroprotective effects documented in the neurodegeneration research. SIRT1 in particular has been extensively studied for neuroprotective effects in Alzheimer and Parkinson disease models. SIRT1 deacetylates multiple substrates including PGC-1 alpha for mitochondrial biogenesis, Foxo transcription factors for oxidative stress response, and histone proteins for chromatin remodeling that supports protective gene expression.

SIRT3, a mitochondrial sirtuin, supports mitochondrial oxidative capacity and mitochondrial antioxidant defense. SIRT6 supports DNA damage response in the nucleus. The integrated sirtuin activity depends critically on NAD+ availability, and restoring brain NAD+ levels through administration or precursor supplementation restores the sirtuin signaling that protects neurons under pathological stress.

The sirtuin neuroprotection research connects to the NAD+ Exercise Research: Physical Performance and Recovery which covers the broader sirtuin biology, and to the NAD+ circadian article which covers the circadian aspects of sirtuin function that are relevant to brain biology.

Neuroinflammation and NAD+

Brain NAD+ decline is associated with increased neuroinflammation through multiple mechanisms. Reduced sirtuin activity fails to suppress NF-kB mediated inflammatory gene expression. Reduced PARP capacity fails to resolve DNA damage that triggers inflammatory responses. Reduced mitochondrial function produces increased reactive oxygen species that activate inflammatory signaling. The combined effects create an increasingly inflammatory brain environment that contributes to neurodegeneration.

Published research on NAD+ restoration documents reduced neuroinflammation markers including reduced microglial activation, reduced pro-inflammatory cytokine expression in brain tissue, and preserved blood brain barrier integrity. The anti-inflammatory effects of NAD+ restoration contribute to the neuroprotection observed in neurodegenerative models.

The neuroinflammation research connects to the VIP neuroinflammation article, the Semax neuroinflammation article, and the GLP-1 SM neuroprotection article. Multiple compounds address neuroinflammation through different primary mechanisms but converge on similar tissue level outcomes.

Mitochondrial Dysfunction in Neurodegeneration

Mitochondrial dysfunction is a shared feature of aging and neurodegenerative pathology. The Where to Buy NAD+ for Research: A Sourcing Guide covers the general mitochondrial biology. For neurodegeneration specifically, mitochondrial dysfunction impairs neuronal energy metabolism in neurons that have the highest metabolic demand in the body, making them particularly vulnerable to energy failure.

NAD+ restoration supports mitochondrial function through multiple pathways including direct provision of the NAD+ substrate for oxidative phosphorylation, SIRT3 mediated support of mitochondrial antioxidant defense, and PGC-1 alpha mediated mitochondrial biogenesis. The combined mitochondrial support preserves neuronal energy capacity under pathological stress.

The mitochondrial research connects to the MOTS-c research cluster through the shared mitochondrial biology. MOTS-c and NAD+ address mitochondrial function through related pathways and represent complementary research tools for mitochondrial neurodegeneration research.

Research Design for Neurodegeneration Studies

Neurodegeneration research with NAD+ requires study designs with sufficient duration for the pathology to develop and for the protective effects to manifest. Transgenic Alzheimer disease models typically require months of follow up for the full pathology to emerge. Acute neurotoxin models develop pathology more rapidly but represent different aspects of the disease biology than the chronic progressive models.

The delivery route affects brain NAD+ levels because of the blood brain barrier considerations. Intraperitoneal and intravenous administration provide systemic exposure that partially reaches the brain. Intracerebroventricular administration provides direct brain delivery but requires specialized surgical preparation. Precursor administration through oral or subcutaneous routes provides an alternative that may achieve better brain penetration than direct NAD+ administration depending on the specific precursor.

The endpoint panel should include cognitive or motor function assessment, histological analysis of the relevant brain regions, molecular markers of the pathology being studied, and measurement of brain NAD+ levels to confirm that the intervention is achieving the target brain exposure.

Research Peptide Referenced

NAD+ 500mg, research grade nicotinamide adenine dinucleotide, third party COA

For complete sourcing details see the NAD+ sourcing guide.

Within the NAD+ cluster:

Related clusters:

Not for human consumption. Research use only.

Explore more peer-reviewed research and laboratory guides from our science team:

All products are third-party tested with a Certificate of Analysis (COA) included. For research use only.

MOTS-C 10mg, 99%+ purity, COA included
NAD+ 500mg, 99%+ purity, COA included
Glutathione 1500mg, 99%+ purity, COA included
VIP 10mg, 99%+ purity, COA included
GLP-1 SM 20mg, 99%+ purity, COA included

Browse All Research Peptides →

Age Verification

NAD+ Neurodegeneration Research: Brain Decline Studies

Frequently Asked Questions

What is NAD+ in research contexts?

Why does brain NAD+ matter in neurodegeneration?

What neurodegeneration models use NAD+ research?

Is NAD+ approved for human use?

Glossary

More from the Blog

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

Brain NAD+ Decline in Aging and Neurodegeneration

Alzheimer Disease Model Research

Parkinson Disease Research

NAD+ Precursor Research in Brain

Sirtuin Mediated Neuroprotection

Neuroinflammation and NAD+

Mitochondrial Dysfunction in Neurodegeneration

Research Design for Neurodegeneration Studies

Research Peptide Referenced

Ready to Start Your Research?

Where can researchers source third-party tested NAD+?

What's the Cheapest Way to Get Tirzepatide (GLP-2 TZ) for Research?

Age Verification

NAD+ Neurodegeneration Research: Brain Decline Studies

Frequently Asked Questions

What is NAD+ in research contexts?

Why does brain NAD+ matter in neurodegeneration?

What neurodegeneration models use NAD+ research?

Is NAD+ approved for human use?

Glossary

More from the Blog

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

Brain NAD+ Decline in Aging and Neurodegeneration

Alzheimer Disease Model Research

Parkinson Disease Research

NAD+ Precursor Research in Brain

Sirtuin Mediated Neuroprotection

Neuroinflammation and NAD+

Mitochondrial Dysfunction in Neurodegeneration

Research Design for Neurodegeneration Studies

Research Peptide Referenced

Related Research Reading

Related Research Articles

Explore Related Products

Ready to Start Your Research?

Where can researchers source third-party tested NAD+?

What's the Cheapest Way to Get Tirzepatide (GLP-2 TZ) for Research?